The recent surge in capital into specialized pharmaceutical companies, particularly those focusing on experimental therapies and complex drug development programs, has fueled what some are calling "High Roller Pharma." While the possibility for revolutionary treatments and significant returns is clear, the connected risks are also considerable. Man